1. Pink Sheet

EQRx Confronts US Drug Development Realities, Shifts Pricing Approach

Company’s $1.5bn To Last Into 2028

 
• By Mandy Jackson

Because of FDA requirements for studies applicable to US patients, EQRx ended US development of its PD-1 inhibitor and will launch its EGFR and CDK4/6 inhibitors at market-based prices.

Red paper plane is different from the white paper plane. business and leadership concept. airplane change direction.
The drug pricing strategy for EQRx's first two products in the US will differ from elsewhere in the world • Source: Shutterstock

EQRx, Inc. says it remains committed to making its drug candidates accessible to patients, but the company’s stated purpose of making its therapies available at the lowest possible prices is turning out to be more challenging than it thought. EQRx announced it is ending US development of its PD-1 inhibitor sugemalimab and significantly delaying the launch of its EGFR inhibitor aumolertinib.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access